Cooperation among the best health professionals / institutions and pharmaceutical companies is an integral part of the healthcare system. As such, it has a positive impact on the quality of care and value for future medical research.Financial-Disclosure
Experts have valuable knowledge about management and treatment of disease, which in turn helps pharmaceutical companies to push the limits of modern medicine. Both sides have met regularly during scientific research, clinical trials, educational activities, etc..
But it is cooperation between experts and industry, which may create the potential for conflicts of interes . Today and every day we witness increasing pressure from the public, media and politicians to be more transparent and clarify these relationships.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is well aware of these pressures and has moved to adopt a Disclosure Code.
The primary objective of this pan-European initiative, which is an American-model Sunshine Act, is to clarify the extent and nature of cooperation between health professionals / institutions and pharmaceutical companies and to clarify the amount of the payments (as is already the case in France and Germany).
Refer to the links below for more information: